Regeneron Pharmaceuticals (REGN) fundamentals: P/E, valuation, undervalued?
Regeneron Pharmaceuticals · Health Care · ref. ETF XLV · price $753.12
In short — Regeneron Pharmaceuticals trades at 18.9× earnings (P/E), 12.2× forward, with a net margin of 27.9 % and revenue growth of +17 %. Read: Cheap for the growth (P/E 12 for ~17% growth (PEG 0.7)).
Is Regeneron Pharmaceuticals stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$753.12+31.5% over range
Oct 14, 25low $569.17 · high $852.03Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
72% recommend buying · 18 analysts
Valuation : Cheap for the growth — P/E 12 for ~17% growth (PEG 0.7)
Valuation
18.9
P/E (price/earnings)
12.2
Forward P/E
—
PEG
2.4
Price/book (P/B)
$77.5B
Market cap
39.93
EPS
Profitability & growth
27.9 %
Net margin
+17 %
Revenue growth
-5 %
Earnings growth
$2.7B
Total debt
Regeneron Pharmaceuticals income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $12.2B | $4.3B | 35.6 % |
| 2023 | $13.1B | $4.0B | 30.1 % |
| 2024 | $14.2B | $4.4B | 31.1 % |
| 2025 | $14.3B | $4.5B | 31.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Regeneron Pharmaceuticals's P/E and is the stock undervalued? What's a good P/E?
Regeneron Pharmaceuticals's P/E is 18.9 (forward 12.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Regeneron Pharmaceuticals profitable?
Regeneron Pharmaceuticals has a net margin of 27.9 % (EPS 39.93). The company is profitable.
Is REGN stock expensive?
Our read: "Cheap for the growth" — P/E 12 for ~17% growth (PEG 0.7). Cross-check with growth and sector.
💬 A question about Regeneron Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Regeneron Pharmaceuticals